VNRX - VolitionRx Limited

NYSE American - NYSE American Delayed Price. Currency in USD
2.19
-0.01 (-0.45%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.20
Open2.25
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.17 - 2.30
52 Week Range2.08 - 4.00
Volume26,300
Avg. Volume140,807
Market Cap65.742M
Beta0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.56
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • VolitionRx Limited (NYSEMKT:VNRX): Time For A Financial Health Check
    Simply Wall St.last month

    VolitionRx Limited (NYSEMKT:VNRX): Time For A Financial Health Check

    VolitionRx Limited (AMEX:VNRX) is a small-cap stock with a market capitalization of US$71.75M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...

  • ACCESSWIRElast month

    SeeThruEquity Issues Update on VolitionRx (VNRX)

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...

  • ACCESSWIRElast month

    Wired News – OpGen Announces Collaborator in Verification Study for Acuitas® Tests

    Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on OpGen, Inc. (NASDAQ: OPGN ). If you want access ...

  • PR Newswirelast month

    VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock

    ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:  VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the closing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share for gross proceeds of $8.4 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Volition.  All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.

  • PR Newswirelast month

    VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

    ISNES, Belgium , March 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective ...

  • PR Newswirelast month

    VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

    Oppenheimer & Co. Inc. is acting as the sole book-running manager for the proposed offering.  National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD), is acting as a co-manager in connection with the offering. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.

  • PR Newswire2 months ago

    VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board

    ISNES, Belgium, March 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr. Lee-Jen Wei, a professor of Biostatistics at Harvard University. Prof. Wei's main area of research is developing statistical methods for the design and analysis of clinical trials. Prof. Wei has developed numerous novel statistical methods used widely and is the author of more than 140 peer-reviewed publications.

  • Zacks Small Cap Research2 months ago

    VNRX: Q4 Results / Operational and Business Update

    By Brian Marckx, CFA NYSE:VNRX VolitionRx (NYSE:VNRX) reported Q4 results and provided a business update.  Relative to the financials, results continue to come in well within our expectations with Q4 operating ...

  • VolitionRx Limited (NYSEMKT:VNRX): Are Analysts Optimistic?
    Simply Wall St.2 months ago

    VolitionRx Limited (NYSEMKT:VNRX): Are Analysts Optimistic?

    VolitionRx Limited’s (AMEX:VNRX): VolitionRx Limited, a life sciences company, focuses on developing blood-based tests to diagnose a range of cancers. The US$84.33M market-cap posted a loss in its most recentRead More...

  • PR Newswire2 months ago

    VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update

    ISNES, Belgium, March 1, 2018 /PRNewswire/ -- VolitionRX Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results for the full fiscal year ended December 31, 2017. Cameron Reynolds, Chief Executive Officer of Volition, upon releasing these results commented, "I could not be more proud of our dedicated team at Volition.  During 2017, we, together with our collaborators, have made strong progress. After seven years of hard work, earlier this week we were excited to announce excellent early detection interim results from our ongoing front-line screening trial for colorectal cancer.

  • PR Newswire2 months ago

    VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update

    Conference call to take place Friday, March 2, 2018 at 8:30 am Eastern time ISNES, Belgium , Feb. 28, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference ...

  • PR Newswire2 months ago

    VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

    This ongoing study is being carried out in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program. The interim results demonstrated that a small panel of three ELISA assays, when considered with the subjects' ages and smoking histories, produced an area under the curve (AUC) of 83% and was able to detect 80% of Stage I CRC cases and 66% of High-Risk Adenomas (HRA) at 78% specificity, respectively.

  • PR Newswire2 months ago

    VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.

    ISNES, Belgium, Feb. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the successful conclusion to the Logistics and Pathway Design Study conducted by Hvidovre Hospital and The Danish Research Group.  The study was established to answer the very practical, logistical questions of how a triage blood test could fit into the current Danish screening program for colorectal cancer ("CRC"). The study showed that it was indeed possible to collect, process, gather and ship the blood test from all five participating hospitals to a central laboratory within 24 hours. Furthermore, analysis from the central laboratory was shown to provide the needed data in due time (in accordance with current Danish Legislation) to decide whether or not to perform a colonoscopy.

  • PR Newswire4 months ago

    VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

    ISNES, Belgium, Jan. 3, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO, Cameron Reynolds updating the company's shareholders. In the letter, Mr. Reynolds outlines several significant accomplishments to date and highlights the fact that the company believes that it is close to achieving a key clinical milestone with the completion of a 680-subject trial for the Nu.QTM Frontline Asymptomatic Colorectal Cancer Screening Test. Volition expects to report the results from this study in early February.

  • PR Newswire5 months ago

    VolitionRx Limited to Attend Conferences in December

    ISNES, Belgium , Dec. 5, 2017 /PRNewswire/ --  VolitionRx Limited  (NYSE American: VNRX) today announced that its Executive Vice President, Scott Powell , is scheduled to attend two conferences in December. ...

  • Zacks Small Cap Research5 months ago

    VNRX: Frontline CRC Studies Read-Out ~1H 2018, Could Be Value-Inflection Event

    By Brian Marckx, CFA NYSE:VNRX Q3 Results / Operational and Business Update:  VolitionRx (NYSE:VNRX) reported Q3 results and provided a business update.  Relative to the financials, results were very much ...

  • PR Newswire5 months ago

    Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies

    ISNES, Belgium, Nov. 10, 2017 /PRNewswire/ -- Singapore Volition Pte. Ltd, a wholly-owned subsidiary of VolitionRx Limited (NYSE American: VNRX) ("Volition"), has entered into a Memorandum of Understanding ("MOU") with the National Taiwan University ("NTU") to conduct two large colorectal cancer (CRC) research studies across the Asia Pacific Region, totaling approximately 7,000 patient samples. "The signing of this MOU is a good start for Volition in the Asia Pacific Region" commented Dr. Jasmine Kway, Volition's Vice President of Asia. "We are fortunate and delighted to be working with a renowned institution and Professor Han-Mo Chiu, a prominent thought leader. The first trial will be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific Region, including 5,000 asymptomatic colorectal cancer screening subjects.

  • ACCESSWIRE5 months ago

    Volitionrx Limited to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Volitionrx Limited (NYSE: VNRX ) will be discussing their earnings results in their Q3 Earnings Call to be held on Friday, November 10, 2017 at 8:30 AM Eastern ...

  • What Investors Should Know About VolitionRx Limited’s (VNRX) Financial Strength
    Simply Wall St.5 months ago

    What Investors Should Know About VolitionRx Limited’s (VNRX) Financial Strength

    Investors are always looking for growth in small-cap stocks like VolitionRx Limited (AMEX:VNRX), with a market cap of USD $78.23M. However, an important fact which most ignore is: how financiallyRead More...

  • Associated Press5 months ago

    VolitionRX reports 3Q loss

    On a per-share basis, the Singapore-based company said it had a loss of 15 cents. In the final minutes of trading on Thursday, the company's shares hit $3.12. A year ago, they were trading at $4.40. _____ ...

  • PR Newswire5 months ago

    VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update

    ISNES, Belgium, Nov. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter ended September 30, 2017. Volition management will host a conference call tomorrow, November 10, at 8:30 a.m. U.S. Eastern Time to discuss these results. Mr. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have made fantastic progress this quarter, moving our clinical product development strongly forward in Asia, Europe and the U.S, and broadening our potential revenue base with our recently announced research kit sales.

  • PR Newswire7 months ago

    VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits

    ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multinational pharmaceutical company. Chief Executive Officer of Volition, Cameron Reynolds, commented, "This is a very important milestone for Volition as it represents our first revenue from the Nu.Q™ platform. The RUO kits could be used to develop a companion diagnostic to a pharmaceutical company's therapeutic product, so could represent an additional potential revenue stream beyond the commercialization of our blood-based cancer tests on the same platform of assays.

  • PR Newswire7 months ago

    VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding

    ISNES, Belgium, Sept. 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded a loan and a non-repayable grant totaling $1.5 million from SOFINEX and the Walloon Region, Belgium. Dr. Gaetan Michel, Chief Executive Officer of Volition's subsidiary, Belgian Volition SPRL, commented, "We are delighted with the financial support that we continue to receive from our local agencies SOFINEX and Namur Invest, as well as the Walloon Region, Belgium.

  • PR Newswire7 months ago

    VolitionRx Announces its European Colorectal Cancer Strategy

    ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe.  As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample), followed by CE marking, with a goal to launch a European frontline CRC screening product in 2018. Chief Executive Officer of Volition, Cameron Reynolds, commented, "We believe that the market for the frontline screening test represents the largest near-term opportunity for Volition, as there are 150 million Europeans of screening age. "We are making significant progress with our frontline CRC screening test," said Dr. Gaetan Michel, Chief Executive Officer of Belgian Volition.

  • PR Newswire7 months ago

    VolitionRx to Attend Two Major Conferences in Asia

    Volition's Vice President of Asia, Dr. Jasmine Kway, commented, "Asia is a very important market for Volition and we have made significant progress in the region since January of this year. There is a growing aging population in many countries in Asia, with more than 40% of worldwide colorectal cancers occurring there. Volition has been developing its position in Asia since the beginning of 2017 and has generated encouraging responses from key opinion leaders (KOLs) in the region.